{"content":"<li class=\"n-box-item date-title\" data-end=\"1526097599\" data-start=\"1526011200\" data-txt=\"Monday, December 23, 2019\">Friday, May 11, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3356028\" data-ts=\"1526075763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3356028-agenusminus-6_5-on-market-sales-deal-for-20m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus -6.5% on at-the-market sales deal for 20M shares</a></h4><ul>   <li>Biotech firm Agenus (NASDAQ:<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a>) is <font color='red'>6.5% lower</font> postmarket after a filing notes it's entered an <a href=\"https://seekingalpha.com/filing/4020345\" target=\"_blank\">at-the-market sales deal</a> covering up to 20M shares.</li>    <li>The company entered the deal with B. Riley FBR.</li>    <li>It can sell the shares through any method deemed to be an at-market offering; B. Riley will earn a commission equal to 3% of gross proceeds of each sale.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3356028\" data-linked=\"Agenus -6.5% on at-the-market sales deal for 20M shares\" data-tweet=\"$AGEN - Agenus -6.5% on at-the-market sales deal for 20M shares https://seekingalpha.com/news/3356028-agenusminus-6_5-on-market-sales-deal-for-20m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3356028-agenusminus-6_5-on-market-sales-deal-for-20m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3356027\" data-ts=\"1526074770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEWT\" target=\"_blank\">NEWT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3356027-after-hours-gainers-losers-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (05/11/2018)</a></h4><ul>     <li><b>Top gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/NEWT' title='Newtek Business Services Inc.'>NEWT</a>&nbsp;<font color='green'>+3.8%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+2.8%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a>&nbsp;<font color='green'>+2.3%</font>. <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='green'>+2.1%</font>. <a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express'>ZTO</a>&nbsp;<font color='green'>+2.0%</font>.</li>     <li><strong>Top Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a>&nbsp;<font color='red'>-2.2%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/ADVM' title='Adverum Biotechnologies, Inc.'>ADVM</a>&nbsp;<font color='red'>-1.5%.&nbsp;</font>GGP&nbsp;<font color='red'>-1.1%</font>. <a href='https://seekingalpha.com/symbol/HLT' title='Hilton Worldwide Holdings'>HLT</a>&nbsp;<font color='red'>-1.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3356027\" data-linked=\"After Hours Gainers / Losers (05/11/2018)\" data-tweet=\"$NEWT $NEWT $ANFI - After Hours Gainers / Losers (05/11/2018) https://seekingalpha.com/news/3356027-after-hours-gainers-losers-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3356027-after-hours-gainers-losers-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355984\" data-ts=\"1526068492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEO\" target=\"_blank\">TEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355984-telecom-argentina-posts-double-digit-gains-in-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telecom Argentina posts double-digit gains in Q1</a></h4><ul>   <li>Telecom Argentina (NYSE:<a href='https://seekingalpha.com/symbol/TEO' title='Telecom Argentina S.A.'>TEO</a>) has slid in U.S. trading, <font color='red'>down 8.8%</font>, after posting <a href=\"https://seekingalpha.com/news/3355968-telecom-argentina-reports-q1-results\" target=\"_blank\">Q1 earnings</a> where it increased revenues and profits by double digits.</li>    <li>Revenues of P$30.7B grew 27.3%; Service revenues were up 26.6% to P$28.5B.</li>    <li>Of those, Mobile services were up 17% to P$10.95B; Internet services grew 41.8% to P$7.15B; Cable TV services up 34.3% to P$6.67B; and Fixed Telephony and Data services up 26% to P$3.63B.</li>    <li>But operating costs rose 20.1% to P$23.6B (a level that was below inflation again).</li>    <li>Mobile subscribers in Argentina came to 19.5M; cable TV subscribers ended up at 3.5M; and broadband accesses totaled 4.1M.</li>    <li>Mobile ARPU of Personal in Argentina rose 20.5% to P$160.8/month; Broadband ARPU rose 51.6% to P$577.6/month; and Cable TV ARPU rose 37.4% to P$636.5/month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355984\" data-linked=\"Telecom Argentina posts double-digit gains in Q1\" data-tweet=\"$TEO - Telecom Argentina posts double-digit gains in Q1 https://seekingalpha.com/news/3355984-telecom-argentina-posts-double-digit-gains-in-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3355984-telecom-argentina-posts-double-digit-gains-in-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355981\" data-ts=\"1526067113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESRX\" target=\"_blank\">ESRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355981-express-scripts-and-cvs-among-those-gaining-after-trump-speech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Express Scripts and CVS among those gaining after Trump speech</a></h4><ul><li>\"President Trump rightly recognizes drug companies charge way too much, and their prices need to come down,\" <a href=\"https://seekingalpha.com/pr/17161259-express-scripts-statement-administrations-comments-drug-pricing\" target=\"_blank\">says</a> Express Scripts (<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='green'>+3.7%</font>) following today's speech.</li><li>\"CVS Health (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='green'>+4.3%</font>) is already well positioned to implement many of the key proposals outlined by the Administration,\" <a href=\"https://seekingalpha.com/pr/17161265-cvs-health-statement-trump-administration-initiative-reduce-drug-costs\" target=\"_blank\">says that company</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355978-drug-sector-move-trump-speech\" target=\"_blank\">Drug sector on the move after Trump speech</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355981\" data-linked=\"Express Scripts and CVS among those gaining after Trump speech\" data-tweet=\"$ESRX $ESRX $CVS - Express Scripts and CVS among those gaining after Trump speech https://seekingalpha.com/news/3355981-express-scripts-and-cvs-among-those-gaining-after-trump-speech?source=tweet\" data-url=\"https://seekingalpha.com/news/3355981-express-scripts-and-cvs-among-those-gaining-after-trump-speech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355978\" data-ts=\"1526066585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355978-drug-sector-on-move-after-trump-speech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug sector on the move after Trump speech</a></h4><ul><li>Not included in the president's speech, note Adam Feuerstein and Damian Garde <a href=\"https://www.statnews.com/2018/05/11/trump-drug-pricing-speech-stocks/\" target=\"_blank\">was the long-feared call </a>for Medicare to negotiate lower prescription drug prices. Also missing, they say, was the loud rhetoric toward pricing that had been a feature of his presidential campaign and early months in office.</li><li>Instead, most of the tough talk was directed at the middlemen who negotiate drug costs for insurance companies, and pharma players have no problem with that.</li><li><a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, and <a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> are all at session highs,&nbsp;<font color='green'>ahead 1.6%</font>,&nbsp;<font color='green'>3.2%</font>, and&nbsp;<font color='green'>2.15%</font>, respectively.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355955-trump-speech-drug-prices-light-specifics\" target=\"_blank\">Trump speech on drug prices light on specifics</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355978\" data-linked=\"Drug sector on the move after Trump speech\" data-tweet=\"$XLV $IBB $IHE - Drug sector on the move after Trump speech https://seekingalpha.com/news/3355978-drug-sector-on-move-after-trump-speech?source=tweet\" data-url=\"https://seekingalpha.com/news/3355978-drug-sector-on-move-after-trump-speech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355977\" data-ts=\"1526066365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SD\" target=\"_blank\">SD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355977-icahn-adds-two-nominees-for-sandridge-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Icahn adds two more nominees for SandRidge board</a></h4><ul>     <li>Carl Icahn discloses <a href=\"https://www.sec.gov/Archives/edgar/data/921669/000081376218000061/sddfan14a051118ex1.htm\" target=\"_blank\">two more nominees</a> for SandRidge Energy&rsquo;s (<a href='https://seekingalpha.com/symbol/SD' title='SandRidge Energy, Inc.'>SD</a> <font color='red'>-2.7%</font>) board, signaling he is <a href=\"https://finance.yahoo.com/news/compromise-rejected-icahn-adds-nominees-160551132.html\" target=\"_blank\">not interested in a compromise</a> over his fight to take control of the company.</li>     <li>Icahn, who already nominated a five-person slate to replace the current board, says he is raising his slate of candidates to seven following SD&rsquo;s announcement <a href=\"https://seekingalpha.com/news/3353040-sandridge-seeks-add-two-icahn-nominees-board\" target=\"_blank\">last week</a> that it was expanding the five-member board in an attempt to make room for two Icahn representatives.</li>     <li>The new nominees are Jonathan Christodoro, a private investor who once served as managing director for Icahn Capital, and Nancy Dunlap, who runs the private family office of former New Jersey Governor Jon Corzine.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355977\" data-linked=\"Icahn adds two more nominees for SandRidge board\" data-tweet=\"$SD - Icahn adds two more nominees for SandRidge board https://seekingalpha.com/news/3355977-icahn-adds-two-nominees-for-sandridge-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3355977-icahn-adds-two-nominees-for-sandridge-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355973\" data-ts=\"1526065578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTEC\" target=\"_blank\">TTEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355973-convergys-up-nearly-12-on-sale-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Convergys up nearly 12% on sale chatter</a></h4><ul><li>The call-center operator <a href=\"https://www.wsj.com/articles/convergys-is-in-talks-with-several-potential-buyers-1526064861\" target=\"_blank\">is in talks with</a> a number of interested parties, according to the WSJ, with the company having begun the sales process after CEO Andrea Ayers decided to exit early this year.</li><li>Potential buyers could be industry peers (<a href='https://seekingalpha.com/symbol/TTEC' title='TTEC Holdings, Inc.'>TTEC</a>, <a href='https://seekingalpha.com/symbol/CNDT' title='Conduent Inc'>CNDT</a> come to mind) or private-equity players. says the story.</li><li><a href='https://seekingalpha.com/symbol/CVG' title='Convergys Corporation'>CVG</a>&nbsp;<font color='green'>+11.7%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3355973\" data-linked=\"Convergys up nearly 12% on sale chatter\" data-tweet=\"$TTEC $TTEC $CNDT - Convergys up nearly 12% on sale chatter https://seekingalpha.com/news/3355973-convergys-up-nearly-12-on-sale-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3355973-convergys-up-nearly-12-on-sale-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355970\" data-ts=\"1526065304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355970-technology-top-5-gainers-losers-of-3_00-pm-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3.00 PM (05/11/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='green'>+20%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PSDO' title='Presidio'>PSDO</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CASA' title='Casa Systems, Inc.'>CASA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BDR' title='Blonder Tongue Laboratories, Inc'>BDR</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355970\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3.00 PM (05/11/2018)\" data-tweet=\"$HEAR $HEAR $TTD - Technology - Top 5 Gainers / Losers as of 3.00 PM (05/11/2018) https://seekingalpha.com/news/3355970-technology-top-5-gainers-losers-of-3_00-pm-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355970-technology-top-5-gainers-losers-of-3_00-pm-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355969\" data-ts=\"1526064891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBE\" target=\"_blank\">OBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355969-obsidian-energy-slips-q1-results-whacked-weaker-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obsidian Energy slips as Q1 results whacked by weaker production</a></h4><ul>     <li>Obsidian Energy (<a href='https://seekingalpha.com/symbol/OBE' title='Obsidian Energy Ltd.'>OBE</a> <font color='red'>-1.7%</font>) slides as much as 4% after swinging to a <a href=\"https://seekingalpha.com/news/3355732-obsidian-energy-reports-q1-results\" target=\"_blank\">Q1 loss</a>, as downtime due to harsh winter conditions in western Canada, third-party maintenance and operational delays hampered production.</li>     <li>OBE's C$0.13/share net loss reverses a $0.05 profit in the year-ago quarter and misses analyst consensus estimate of a $0.07, while revenues fell 23% Y/Y to $1M.</li>     <li>OBE says it produced 29,443 boe/day during the quarter, down 6% Q/Q, and operating costs of $14.86/boe came in 3% higher than in Q4 2017.</li>     <li>Despite the temporary production and cash flow impacts in the quarter, OBE continues to expect FY 2018 production and operating costs within guidance ranges, as production levels increased in April.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355969\" data-linked=\"Obsidian Energy slips as Q1 results whacked by weaker production\" data-tweet=\"$OBE - Obsidian Energy slips as Q1 results whacked by weaker production https://seekingalpha.com/news/3355969-obsidian-energy-slips-q1-results-whacked-weaker-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3355969-obsidian-energy-slips-q1-results-whacked-weaker-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355967\" data-ts=\"1526064032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355967-qualcomm-extends-nxp-tender-to-may-25-tendered-shares-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm extends NXP tender to May 25; tendered shares drop</a></h4><ul><li>        Qualcomm (<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a> <font color='green'>+0.5%</font>) yet again <a href=\"https://www.qualcomm.com/news/releases/2018/05/11/qualcomm-extends-cash-tender-offer-all-outstanding-shares-nxp\" target=\"_blank\">extends</a> its tender offer for NXP Semiconductors (<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a> <font color='red'>-0.7%</font>) as the companies await regulatory approval in China. The offer now expires May 25.</li><li>               The number of tendered shares is now 45,135,726 or 13.1% of outstanding common shares, which is down from the 16.2% tendered as of the last extension.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3345529-qualcomm-extends-nxp-offer-period-tendered-shares-increase\" target=\"_blank\">Qualcomm extends NXP offer period, tendered shares increase</a> (April 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355967\" data-linked=\"Qualcomm extends NXP tender to May 25; tendered shares drop\" data-tweet=\"$QCOM $QCOM $NXPI - Qualcomm extends NXP tender to May 25; tendered shares drop https://seekingalpha.com/news/3355967-qualcomm-extends-nxp-tender-to-may-25-tendered-shares-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3355967-qualcomm-extends-nxp-tender-to-may-25-tendered-shares-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355952\" data-ts=\"1526063879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AL\" target=\"_blank\">AL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355952-air-lease-corp-down-2-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Air Lease Corp down 2% post Q1 results</a></h4><ul><li>Air Lease Corp (<a href='https://seekingalpha.com/symbol/AL' title='Air Lease Corp'>AL</a> <font color='red'>-2.8%</font>) <a href=\"https://seekingalpha.com/filing/4017279\" target=\"_blank\">reports Q1</a> revenue growth of +5.8% Y/Y to $381.21M.</li><li>Aggregate fleet net book value of $13.6B (+2.3% Q/Q); Weighted-average fleet age of 3.9 years; Weighted-average remaining lease term of 6.7 years.</li><li>Total fleet of 674 (+1.8% Q/Q) where, Owned aircraft were 253 (+3.7% Q/Q); Managed fleet of 49 (-2% Q/Q) &amp; Order book of 372 (+1.1% Q/Q).</li><li>Total committed rentals were 23.5B&nbsp;(0.4% Q/Q) where&nbsp;Current fleet contracted rentals were&nbsp;$10.2B (+1% Q/Q) &amp; Committed fleet rentals of $13.3B (flat Q/Q).</li><li>Q1 ended with total debt financing, net of discounts &amp; issuance costs, of $9.9B, resulting in a debt to equity ratio of 2.34:1.</li><li>Debt financing was comprised of unsecured debt of $9.5B representing 95.0% of our debt portfolio. Fixed rate debt was&nbsp;<font color='green'>up 570 bps</font>&nbsp;Q/Q to 91.1% &amp; composite interest rate&nbsp;increased to 3.28%.</li><li>Adj. pre-tax return on equity <font color='red'>declined 150 bps</font>&nbsp;to 17.3% &amp; Adj. profit before tax&nbsp;<font color='red'>declined 150 bps</font>&nbsp;to 40.1%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355418-air-lease-eps-line-misses-revenue\" target=\"_blank\">Air Lease EPS in-line, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355952\" data-linked=\"Air Lease Corp down 2% post Q1 results\" data-tweet=\"$AL - Air Lease Corp down 2% post Q1 results https://seekingalpha.com/news/3355952-air-lease-corp-down-2-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355952-air-lease-corp-down-2-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355965\" data-ts=\"1526063689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPRT\" target=\"_blank\">WPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355965-westport-fuelminus-9-oppenheimer-keeps-buy-rating-lifts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westport Fuel -9% but Oppenheimer keeps Buy rating, lifts price target</a></h4><ul>     <li>Westport Fuel Systems (<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-9.6%</font>) has turned sharply lower after reporting a <a href=\"https://seekingalpha.com/news/3355808-westport-fuel-plus-3-percent-q1-loss-edges-lower-year-ago\" target=\"_blank\">smaller than expected Q1 loss</a> but a decline in gross margin due to lower service revenues and the ramp-up of Westport HPDI 2.0.</li>     <li>Oppenheimer analyst Colin Rusch <a href=\"http://www.analystratings.com/articles/westport-innov-receives-a-buy-from-oppenheimer/\" target=\"_blank\">maintains his Buy rating</a> and raises its stock price target to $4 from $3.50, saying WPRT&rsquo;s restructuring is \"paying dividends and the important growth drivers are in place with HPDI 2.0, a broad portfolio that even reaches into hydrogen-based vehicles.\"</li>     <li>Investors should be encouraged by WPRT providing full-year guidance, even as it is roughly in line with Street expectations, Rusch says, adding that Total's <a href=\"https://seekingalpha.com/news/3355193-total-buy-25-percent-stake-clean-energy-fuels-becoming-top-shareholder\" target=\"_blank\">purchase of a stake</a> in Clean Energy Fuels is \"evidence of the ongoing diversification of  transportation fuels... WPRT has both a strong IP and product position to benefit from that diversification.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355965\" data-linked=\"Westport Fuel -9% but Oppenheimer keeps Buy rating, lifts price target\" data-tweet=\"$WPRT - Westport Fuel -9% but Oppenheimer keeps Buy rating, lifts price target https://seekingalpha.com/news/3355965-westport-fuelminus-9-oppenheimer-keeps-buy-rating-lifts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3355965-westport-fuelminus-9-oppenheimer-keeps-buy-rating-lifts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355964\" data-ts=\"1526063574\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WOW\" target=\"_blank\">WOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355964-wow-soars-33-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WOW! soars 33% after earnings</a></h4><ul><li>Q1 revenue of $285.5M slipped 4.8% Y/Y and missed estimates by nearly $4M, but adjusted EPS of $0.19 per share topped consensus by $0.03.</li><li>HSD RGU net additions of 8.7K for the quarter; backing out Edge-Outs net additions were 6.6K.</li><li>Business services subscription revenue, including acquisitions and dispositions up 14.6% Y/Y.</li><li>Company bought back more than 5M shares during Q1, completing $50M program. A new $25M program is approved and Crestview Partners plans to add up to $25M to its stake.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355740-wideopenwest-beats-0_03-misses-revenue\" target=\"_blank\">WideOpenWest beats by $0.03, misses on revenue</a> (May 11)</li><li><a href='https://seekingalpha.com/symbol/WOW' title='WideOpenWest, Inc.'>WOW</a>&nbsp;<font color='green'>+33.3%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3355964\" data-linked=\"WOW! soars 33% after earnings\" data-tweet=\"$WOW - WOW! soars 33% after earnings https://seekingalpha.com/news/3355964-wow-soars-33-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3355964-wow-soars-33-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355955\" data-ts=\"1526063119\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355955-trump-speech-on-drug-prices-light-on-specifics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump speech on drug prices light on specifics</a></h4><ul><li>Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First:</li><li>Bans pharmacist gag rule against advising patients on pricing.</li><li>FDA will accelerate approval process for generics and biosimilars.</li><li>Will \"fix\" price disparity between U.S. and foreign markets (specifics not provided).</li><li>HHS Secretary Alex Azar: plan will leverage private sector dynamics. Will investigate having the FDA mandate the disclosure of pricing in TV drug ads.</li><li>More details to follow in a press briefing.</li><li>Selected tickers: <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a>, <a href='https://seekingalpha.com/symbol/VHT' title='Vanguard Health Care ETF'>VHT</a>, <a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a>, <a href='https://seekingalpha.com/symbol/IYH' title='iShares U.S. Healthcare ETF'>IYH</a>, <a href='https://seekingalpha.com/symbol/RYH' title='Invesco S&P Equal Weight Health Care ETF'>RYH</a>, <a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a>, <a href='https://seekingalpha.com/symbol/PJP' title='Invesco Dynamic Pharmaceuticals Portfolio ETF'>PJP</a>, <a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a>, <a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a>, <a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a>, <a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a>, <a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>, <a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>, <a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>, <a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>, <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>, <a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>, <a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>, <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>, <a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>, <a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>, <a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>, <a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>, <a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>, <a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>, <a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>, <a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>, VRX, <a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>, <a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a>, <a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a></li><li><strong>Update</strong>: Per the <a href=\"https://endpts.com/trump-vows-sweeping-action-to-lower-drug-prices-in-a-speech-long-on-promises-short-on-tough-measures/\" target=\"_blank\">HHS briefing</a>, value-based drug contracting will be added; Medicare Part D formulary will be changed to allow for a minimum of one drug per category instead of two to promote more competition; giving Part D plans more flexibility on adding generics to formularies; end 180-day market exclusivity provision for new generics (temporary provision); new rules aimed at lowering out-of-pocket expenses; targeting lower ex-U.S. drug prices by first analyzing prices in OECD countries and encouraging states to try pilot projects to lower prices.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355955\" data-linked=\"Trump speech on drug prices light on specifics\" data-tweet=\"$AMGN $XLV $VHT - Trump speech on drug prices light on specifics https://seekingalpha.com/news/3355955-trump-speech-on-drug-prices-light-on-specifics?source=tweet\" data-url=\"https://seekingalpha.com/news/3355955-trump-speech-on-drug-prices-light-on-specifics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>224&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355961\" data-ts=\"1526062934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XONE\" target=\"_blank\">XONE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355961-exoneminus-8_8-on-q1-misses-3d-peers-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ExOne -8.8% on Q1 misses; 3D peers drop</a></h4><ul><li>        ExOne (NASDAQ:<a href='https://seekingalpha.com/symbol/XONE' title='ExOne'>XONE</a>)&nbsp;<font color='red'>drops 8.8%</font>&nbsp;on Q1 results that missed EPS and revenue estimates. &nbsp;Reaffirmed FY18 guidance has over 20% revenue growth, $6M to $8M in increased R&amp;D spend, and gross margin improvement.</li><li>                  <a href=\"https://seekingalpha.com/pr/17160405-exone-company-reports-2018-first-quarter-results\" target=\"_blank\">Press release</a> / <a href=\"https://seekingalpha.com/article/4172648-exone-2018-q1-results-earnings-call-slides\" target=\"_blank\">Earnings slides</a> with guidance   </li><li>               3D printing peers in motion: Stratasys (<a href='https://seekingalpha.com/symbol/SSYS' title='Stratasys, Inc.'>SSYS</a> <font color='red'>-2.2%</font>), 3D Systems (<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='red'>-4.9%</font>), Voxeljet (<a href='https://seekingalpha.com/symbol/VJET' title='voxeljet AG'>VJET</a>).&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355510-exone-misses-0_07-misses-revenue\" target=\"_blank\">ExOne misses by $0.07, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355961\" data-linked=\"ExOne -8.8% on Q1 misses; 3D peers drop\" data-tweet=\"$XONE $XONE $SSYS - ExOne -8.8% on Q1 misses; 3D peers drop https://seekingalpha.com/news/3355961-exoneminus-8_8-on-q1-misses-3d-peers-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3355961-exoneminus-8_8-on-q1-misses-3d-peers-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355936\" data-ts=\"1526061880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPJ\" target=\"_blank\">HPJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355936-highpower-international-down-9-weak-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Highpower International down 9%, weak margins</a></h4><ul><li>Highpower International (<a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='red'>-9.7%</font>) reported Q1 revenue growth of 18.9% Y/Y to $49.97M. Lithium business segment net sales were up 33.1% Y/Y to $36.6M.</li><li>Q1 Margins: Gross was&nbsp;<font color='red'>down by 853 bps&nbsp;</font>to 15.2%, operating was&nbsp;<font color='red'>down by 1,1165 bps</font>&nbsp;to -4.2% and EBITDA was&nbsp;<font color='red'>down by 1,076 bps</font>&nbsp;to 1.18%.</li><li>R&amp;D expenses were $2.56M (+29.9% Y/Y) company plans to continue investing in R&amp;D activities, S&amp;D expenses were $1.97M (+17.08% Y/Y) and G&amp;A expenses were $4.11M (+25.7% Y/Y).</li><li>In Q1 company signed an investment agreement of $0.8M for 49% stake in Shenzhen V-power Innovative Technology Co.</li><li>2Q18 Outlook: Revenue growth 30% Y/Y.</li><li>FY18 Outlook: Revenue growth of 20% Y/Y.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355752-highpower-international-reports-q1-results\" target=\"_blank\">Highpower International reports Q1 results</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355936\" data-linked=\"Highpower International down 9%, weak margins\" data-tweet=\"$HPJ - Highpower International down 9%, weak margins https://seekingalpha.com/news/3355936-highpower-international-down-9-weak-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3355936-highpower-international-down-9-weak-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355957\" data-ts=\"1526061616\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRK\" target=\"_blank\">CRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355957-energy-materials-top-5-gainers-losers-of-2-00-pm-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/11/2018)</a></h4><ul>     <li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/MCEP' title='Mid-Con Energy Partners'>MCEP</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/GCP' title='GCP Applied Technologies Inc.'>GCP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/PFIE' title='Profire Energy, Inc.'>PFIE</a> <font color='green'>+6%</font>.</li>      <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNDE' title='Sundance Energy Australia'>SNDE</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355957\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/11/2018)\" data-tweet=\"$CRK $CRK $MCEP - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (05/11/2018) https://seekingalpha.com/news/3355957-energy-materials-top-5-gainers-losers-of-2-00-pm-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355957-energy-materials-top-5-gainers-losers-of-2-00-pm-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355953\" data-ts=\"1526060189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355953-omeros-up-23-on-preparations-for-bla-for-oms721\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros up 23% on preparations for BLA for OMS721</a></h4><ul><li>Ignoring tepid <a href=\"https://seekingalpha.com/pr/17160291-omeros-corporation-reports-first-quarter-2018-financial-results\" target=\"_blank\">Q1 results</a>, investors are moving into Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+23.4%</font>) after the company announced initial preparations for a U.S. marketing application for OMS721 for HSCT-TMA.</li><li>The FDA has requested a further characterization of patients treated with OMS721, additional information on the historical control population and an analysis plan to assess biomarker data. Consistent with accelerated approval, the company would concurrently conduct a confirmatory study prior to full approval. It expects to commence a rolling BLA submission later this year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355431-omeros-misses-0_05-misses-revenue\" target=\"_blank\">Omeros misses by $0.05, misses on revenue</a> (May 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3349443-fda-designates-omeros-oms721-accelerated-review-stem-cell-transplant-associated-clotting\" target=\"_blank\">FDA designates Omeros' OMS721 for accelerated review for stem cell transplant-associated clotting disorder; shares up 9%</a> (April 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355953\" data-linked=\"Omeros up 23% on preparations for BLA for OMS721\" data-tweet=\"$OMER - Omeros up 23% on preparations for BLA for OMS721 https://seekingalpha.com/news/3355953-omeros-up-23-on-preparations-for-bla-for-oms721?source=tweet\" data-url=\"https://seekingalpha.com/news/3355953-omeros-up-23-on-preparations-for-bla-for-oms721\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355949\" data-ts=\"1526058843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMR\" target=\"_blank\">IMMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355949-immersionplus-6_3-on-q1-beats-upside-fy-rev-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immersion +6.3% on Q1 beats, upside FY rev outlook</a></h4><ul><li>        Immersion (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a>) shares are&nbsp;<font color='green'>up 6.3%</font>&nbsp;on Q1 results that beat EPS and revenue estimates with a 827% Y/Y revenue growth. FY18 guidance has upside revenue of $108M to $118M (consensus: $87.19M) and non-GAAP net income of $59M to $67M.</li><li>               <a href=\"https://seekingalpha.com/pr/17160402-immersion-corporation-reports-results-first-quarter-2018\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355512-immersion-beats-0_99-beats-revenue\" target=\"_blank\">Immersion beats by $0.99, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355949\" data-linked=\"Immersion +6.3% on Q1 beats, upside FY rev outlook\" data-tweet=\"$IMMR - Immersion +6.3% on Q1 beats, upside FY rev outlook https://seekingalpha.com/news/3355949-immersionplus-6_3-on-q1-beats-upside-fy-rev-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3355949-immersionplus-6_3-on-q1-beats-upside-fy-rev-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355946\" data-ts=\"1526058127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLOB\" target=\"_blank\">GLOB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355946-globantplus-9_1-on-q1-beats-upside-q2-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globant +9.1% on Q1 beats, upside Q2 outlook</a></h4><ul><li>        Globant (NYSE:<a href='https://seekingalpha.com/symbol/GLOB' title='Globant'>GLOB</a>)&nbsp;<font color='green'>gains 9.1%</font>&nbsp;on Q1 results that beat EPS and revenue estimates with a 35% Y/Y revenue growth. Upside Q2 guidance has revenue of $124M to $126M (consensus: $120.73M; +26% Y/Y at midpoint) with EPS of $0.36 to $0.40 (consensus: $0.36).</li><li>                  In-line FY18 guidance has revenue from $502M to $510M (consensus: $504.06M; +22% at midpoint) and EPS of $1.56 to $1.64 (consensus: $1.58).    </li><li>               <a href=\"https://seekingalpha.com/pr/17160428-globant-reports-2018-first-quarter-financial-results\" target=\"_blank\">Press release.</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355494-globant-beats-0_04-beats-revenue\" target=\"_blank\">Globant beats by $0.04, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355946\" data-linked=\"Globant +9.1% on Q1 beats, upside Q2 outlook\" data-tweet=\"$GLOB - Globant +9.1% on Q1 beats, upside Q2 outlook https://seekingalpha.com/news/3355946-globantplus-9_1-on-q1-beats-upside-q2-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3355946-globantplus-9_1-on-q1-beats-upside-q2-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355945\" data-ts=\"1526058061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNJR\" target=\"_blank\">DNJR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355945-financials-top-gainers-losers-of-1-00-pm-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top Gainers / Losers as of 1:00 PM (05/11/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DNJR' title='Golden Bull Ltd'>DNJR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/WRLD' title='World Acceptance Corporation'>WRLD</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> RFT <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355945\" data-linked=\"Financials - Top Gainers / Losers as of 1:00 PM (05/11/2018)\" data-tweet=\"$DNJR $DNJR $WRLD - Financials - Top Gainers / Losers as of 1:00 PM (05/11/2018) https://seekingalpha.com/news/3355945-financials-top-gainers-losers-of-1-00-pm-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355945-financials-top-gainers-losers-of-1-00-pm-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355942\" data-ts=\"1526057568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVE\" target=\"_blank\">INVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355942-identivplus-15_2-on-q1-revenue-beat-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Identiv +15.2% on Q1 revenue beat, in-line guidance</a></h4><ul><li>        Identiv (NASDAQ:<a href='https://seekingalpha.com/symbol/INVE' title='Identiv, Inc.'>INVE</a>)&nbsp;<font color='green'>gains 15.2%</font>&nbsp;to $3.87 on Q1 results that beat revenue estimates. FY18 guidance has revenue of $74M to $78M (consensus: $75.18M from one analyst) and adjusted EBITDA from $4M to $6M.&nbsp;</li><li>        <a href=\"https://seekingalpha.com/pr/17160341-identiv-reports-first-quarter-2018-results\" target=\"_blank\">Press release</a>. &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355491-identive-eps-0_15\" target=\"_blank\">Identive EPS of -$0.15</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355942\" data-linked=\"Identiv +15.2% on Q1 revenue beat, in-line guidance\" data-tweet=\"$INVE - Identiv +15.2% on Q1 revenue beat, in-line guidance https://seekingalpha.com/news/3355942-identivplus-15_2-on-q1-revenue-beat-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3355942-identivplus-15_2-on-q1-revenue-beat-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355939\" data-ts=\"1526057118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOSY\" target=\"_blank\">MOSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355939-mosysplus-23-on-q1-beats-upside-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoSys +23% on Q1 beats, upside revenue guidance</a></h4><ul><li>        MoSys (NASDAQ:<a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a>)&nbsp;<font color='green'>gains 23%</font>&nbsp;to $1.87 after Q1 results that beat EPS and revenue estimates with a 247% Y/Y revenue growth. Q2 guidance has upside revenue of $4.3M to $4.5M (consensus: $4.19M from one analyst) and operating expenses from $2.2M to $2.4M.</li><li>               <a href=\"https://seekingalpha.com/pr/17160358-mosys-inc-reports-first-quarter-2018-financial-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355463-mosys-beats-0_10-beats-revenue\" target=\"_blank\">MoSys beats by $0.10, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355939\" data-linked=\"MoSys +23% on Q1 beats, upside revenue guidance\" data-tweet=\"$MOSY - MoSys +23% on Q1 beats, upside revenue guidance https://seekingalpha.com/news/3355939-mosysplus-23-on-q1-beats-upside-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3355939-mosysplus-23-on-q1-beats-upside-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355935\" data-ts=\"1526056861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355935-midday-gainers-losers-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (05/11/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+83%</font>. <a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='green'>+48%</font>. <a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/WOW' title='WideOpenWest, Inc.'>WOW</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/BLNK' title='Blink Charging Co.'>BLNK</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EOLS' title='Evolus, Inc.'>EOLS</a> <font color='green'>+17%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='red'>-43%</font>. <a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies Inc.'>SBOT</a> <font color='red'>-43%</font>. <a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/PSDO' title='Presidio'>PSDO</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='red'>-13%</font>.</li>     &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3355935\" data-linked=\"Midday Gainers / Losers (05/11/2018)\" data-tweet=\"$ANFI $ANFI $HEAR - Midday Gainers / Losers (05/11/2018) https://seekingalpha.com/news/3355935-midday-gainers-losers-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355935-midday-gainers-losers-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355934\" data-ts=\"1526056611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPP\" target=\"_blank\">WPP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355934-ft-ex-aol-chief-armstrong-prospect-for-wpp-ceo-job\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Ex-AOL chief Armstrong a prospect for WPP CEO job</a></h4><ul>   <li>Former AOL CEO Tim Armstrong is on the short list of execs who might <a href=\"https://www.ft.com/content/04103e7e-5536-11e8-b3ee-41e0209208ec\" target=\"_blank\">take over from Martin Sorrell</a> at the helm of ad giant <a href='https://seekingalpha.com/symbol/WPP' title='WPP Plc'>WPP</a>, the <i>Financial Times</i> reports.</li>    <li>Armstrong, now CEO of Verizon's Oath (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='green'>+3.2%</font>), is one of a number of external options that WPP is considering, including Unilever's (<a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>, <a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>) chief marketing and communications officer, Keith Weed.</li>    <li>Sorrell built WPP into a global advertising force before <a href=\"https://seekingalpha.com/news/3345663-embattled-sorrell-exits-ceo-post-wpp\" target=\"_blank\">resigning the CEO post</a> under an investigation for personal misconduct last month.</li>    <li>Armstrong ran AOL until its $4.4B sale to Verizon three years ago.</li>    <li>WPP is <font color='green'>up 0.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355934\" data-linked=\"FT: Ex-AOL chief Armstrong a prospect for WPP CEO job\" data-tweet=\"$WPP $WPP $UL - FT: Ex-AOL chief Armstrong a prospect for WPP CEO job https://seekingalpha.com/news/3355934-ft-ex-aol-chief-armstrong-prospect-for-wpp-ceo-job?source=tweet\" data-url=\"https://seekingalpha.com/news/3355934-ft-ex-aol-chief-armstrong-prospect-for-wpp-ceo-job\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355930\" data-ts=\"1526055872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBS\" target=\"_blank\">AMBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355930-amarantus-up-28-on-financing-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarantus up 28% on financing plan</a></h4><ul><li>Nano cap Amarantus BioScience Holdings (<a href='https://seekingalpha.com/symbol/AMBS' title='Amarantus Bioscience Holdings, Inc.'>OTCPK:AMBS</a> <font color='green'>+27.8%</font>) is up on below-average volume on the heels of its plan to <a href=\"https://seekingalpha.com/pr/17161092-amarantus-provides-business-overview\" target=\"_blank\">raise additional capital</a> under the JOBS Act. It says it is in active discussions with advisors and investment banks to advance the effort.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355930\" data-linked=\"Amarantus up 28% on financing plan\" data-tweet=\"$AMBS - Amarantus up 28% on financing plan https://seekingalpha.com/news/3355930-amarantus-up-28-on-financing-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3355930-amarantus-up-28-on-financing-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355928\" data-ts=\"1526055781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNA\" target=\"_blank\">CDNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355928-caredx-down-1_8-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CareDx down 1.8% post Q1 results</a></h4><ul><li>CareDx (<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='red'>-1.7%</font>)&nbsp;<a href=\"https://seekingalpha.com/filing/4017385\" target=\"_blank\">reports Q1</a> revenue growth of 21.3% Y/Y to $14.05M.</li><li>Testing revenue was $10.6M (+34.2% Y/Y)&nbsp;with 1,051 AlloSure &amp; 3,847 AlloMap patient results provided&nbsp;&amp; Product revenue of $3.3M (-10.8% Y/Y).</li><li>The company entered into partnership with Illumina to develop &amp; sell it's Next Generation Sequencing transplant solutions.</li><li>Also, launched HeartCare, a comprehensive solution for surveillance of heart transplant patients, combining AlloMap with AlloSure-Heart.</li><li>Validates Olerup QTYPE on multiple platforms &amp; receives CE mark certification.</li><li>Cash &amp; equivalents were $18.7M (+10.7% Q/Q) &amp; debt of $15M.</li><li><strong>2018 Outlook:&nbsp;</strong>Revenue of $64-66M, Adj.&nbsp;EBITDA profitability expected during H2 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355413-caredx-misses-0_01-beats-revenue\" target=\"_blank\">CareDx misses by $0.01, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355928\" data-linked=\"CareDx down 1.8% post Q1 results\" data-tweet=\"$CDNA - CareDx down 1.8% post Q1 results https://seekingalpha.com/news/3355928-caredx-down-1_8-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355928-caredx-down-1_8-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355923\" data-ts=\"1526054439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355923-consumer-top-gainers-losers-of-12-00-pm-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (05/11/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/OTIV' title='On Track Innovations Ltd'>OTIV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355923\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (05/11/2018)\" data-tweet=\"$ANFI $ANFI $MCFT - Consumer - Top Gainers / Losers as of 12:00 PM (05/11/2018) https://seekingalpha.com/news/3355923-consumer-top-gainers-losers-of-12-00-pm-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355923-consumer-top-gainers-losers-of-12-00-pm-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355924\" data-ts=\"1526054418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMRT\" target=\"_blank\">SMRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355924-stein-mart-continues-to-soar-who-called\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stein Mart continues to soar, here&#39;s who called it</a></h4><ul> <li>Stein Mart (NASDAQ:<a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a>) is <font color='green'>up 14.1%</font> on the day and 144% for the year in a retail recovery not widely predicted.</li> <li>A call-out is in order for SA contributors <a href=\"https://seekingalpha.com/article/4157390-stein-mart-risen-grave-better-think\" target=\"_blank\">Jeremy Blum</a> and <a href=\"https://seekingalpha.com/article/4157111-stein-mart-soared-go-higher\" target=\"_blank\">Courage &amp; Conviction Investing</a> for their March articles pointing to upside on Stein Mart when the stock traded at less than a third of where it does today.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3355924\" data-linked=\"Stein Mart continues to soar, here&#39;s who called it\" data-tweet=\"$SMRT - Stein Mart continues to soar, here&#39;s who called it https://seekingalpha.com/news/3355924-stein-mart-continues-to-soar-who-called?source=tweet\" data-url=\"https://seekingalpha.com/news/3355924-stein-mart-continues-to-soar-who-called\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355918\" data-ts=\"1526053613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355918-viveve-medical-down-38-on-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViVeve Medical down 38% on Q1 results</a></h4><ul><li>Thinly traded nano cap Viveve Medical (<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='red'>-37.7%</font>) slumps on almost a 10x surge in volume after posting <a href=\"https://seekingalpha.com/pr/17160370-viveve-reports-first-quarter-2018-financial-results\" target=\"_blank\">Q1 results</a> that fell shy of expectations.</li><li>Sales were up almost 22% at $3.70M, but consensus was $4.74M. Viveve systems sold totaled 53, 38 in North America.</li><li>2018 revenue guidance reiterated at $22M - 24M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355592-viveve-medical-misses-0_12-misses-revenue\" target=\"_blank\">Viveve Medical misses by $0.12, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355918\" data-linked=\"ViVeve Medical down 38% on Q1 results\" data-tweet=\"$VIVE - ViVeve Medical down 38% on Q1 results https://seekingalpha.com/news/3355918-viveve-medical-down-38-on-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355918-viveve-medical-down-38-on-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355917\" data-ts=\"1526053302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSU\" target=\"_blank\">TSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355917-brazils-timminus-4_9-barclays-cuts-to-equal-weight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil&#39;s TIM -4.9% as Barclays cuts to Equal Weight</a></h4><ul>   <li>TIM Participa&ccedil;&otilde;es (NYSE:<a href='https://seekingalpha.com/symbol/TSU' title='TIM Participaes S.A.'>TSU</a>) is <font color='red'>4.9% lower</font> after Barclays' move to downgrade the company's ADRs to Equal Weight from Overweight.</li>    <li>The firm trimmed its price target to $20.50; the shares had closed at $20.54 yesterday and are down to $19.54 today.</li>    <li>Overall analyst sentiment is still bullish with more Buys than Holds.</li>    <li>Shares are <font color='red'>down 13.4%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355917\" data-linked=\"Brazil&#39;s TIM -4.9% as Barclays cuts to Equal Weight\" data-tweet=\"$TSU - Brazil&#39;s TIM -4.9% as Barclays cuts to Equal Weight https://seekingalpha.com/news/3355917-brazils-timminus-4_9-barclays-cuts-to-equal-weight?source=tweet\" data-url=\"https://seekingalpha.com/news/3355917-brazils-timminus-4_9-barclays-cuts-to-equal-weight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355877\" data-ts=\"1526053057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWCO\" target=\"_blank\">CWCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355877-on-consolidated-waters-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Consolidated Water&#39;s Q1 results</a></h4><ul><li>Consolidated Water (<a href='https://seekingalpha.com/symbol/CWCO' title='Consolidated Water Co. Ltd.'>CWCO</a> <font color='green'>+2.2%</font>) reported Q1 revenue of $15.3M (-2.4% Y/Y). Segment revenues: Retails was $6.43M (-0.7% Y/Y), bulk was $8.23M (+6.54% Y/Y), services were $0.12M (-5.2% Y/Y) and manufacturing was $0.55M (-149.6% Y/Y).</li><li>Q1 overall gross margin&nbsp;<font color='red'>declined by 53 bps</font>&nbsp;to 43.1%. Segment gross margins: Retail&nbsp;<font color='red'>declined by 149 bps</font>&nbsp;to 57.1%, bulk&nbsp;<font color='red'>declined by 34 bps</font>&nbsp;to 34.42%, services&nbsp;<font color='red'>declined by 3,054 bps</font>&nbsp;to 8.9% and manufacturing&nbsp;<font color='red'>declined by 393 bps&nbsp;</font>to 20.6%.</li><li>Q1 operating margin&nbsp;<font color='red'>declined by 108 bps</font>&nbsp;to 11.9%.</li><li>Company signed subscription agreement for the equity funding of&nbsp;Rosarito&nbsp;with SUEZ and Greenfield.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355615-consolidated-water-misses-0_04-misses-revenue\" target=\"_blank\">Consolidated Water misses by $0.04, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355877\" data-linked=\"More on Consolidated Water&#39;s Q1 results\" data-tweet=\"$CWCO - More on Consolidated Water&#39;s Q1 results https://seekingalpha.com/news/3355877-on-consolidated-waters-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355877-on-consolidated-waters-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355876\" data-ts=\"1526052813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RICK\" target=\"_blank\">RICK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355876-rci-hospitality-holdings-up-2_3-due-to-stronger-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RCI Hospitality Holdings up 2.3% due to stronger margins</a></h4><ul><li>RCI Hospitality Holdings (<a href='https://seekingalpha.com/symbol/RICK' title='RCI Hospitality Holdings, Inc.'>RICK</a> <font color='green'>+3.5%</font>) <a href=\"https://seekingalpha.com/filing/4017703\" target=\"_blank\">reports Q1</a> revenue growth of 19.4% Y/Y to $41.23M of which&nbsp;Alcoholic beverages was&nbsp;$17.4M (+22.0% Y/Y); Service revenues $16.1M(+13.9% Y/Y) &amp; Food $5.4M (24.6%).</li><li>Q1 overall margins: Gross&nbsp;<font color='green'>increased 80 bps</font>&nbsp;to 86.4%; Adj. operating&nbsp;<font color='green'>increased 341 bps</font>&nbsp;to 25.7% &amp; Adj. EBITDA&nbsp;<font color='green'>increased 314 bps</font>&nbsp;to 30.1%;&nbsp;revenues &amp; margins benefited from improved portfolio of nightclubs &amp; restaurants, expanded operating leverage from higher sales &amp; increased customer counts.</li><li>Nightclubs segment: Due to higher spend per customer, revenue was $35.4M (+18.3% Y/Y); Same-store sales increased 5.1% &amp; adj. operating margin was marginally&nbsp;<font color='red'>down 10 bps</font>&nbsp;to 35.1%.</li><li>Bombshells segment: An updated menu featuring new items, increased revenue by 28% Y/Y to $5.6M; Same-store sales increased 2.7% &amp; adj. operating margin&nbsp;<font color='green'>increased 200 bps</font>&nbsp;to 20.8%.</li><li>Adj. corporate overhead declined to 7.2% from 11.8% &amp; Occupancy costs declined 30 bps to 7.4%.</li><li>FCF grew 8.8% Y/Y to $5.3M; Cash &amp; equivalents of $12.5M (+4.6% Q/Q).</li><li><strong>2018 Outlook:</strong> FCF of $23M, based on estimated CFO of ~$25.5M &amp; Capex of ~$2.5M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355436-rci-hospitality-holdings-beats-0_14-beats-revenue\" target=\"_blank\">RCI Hospitality Holdings beats by $0.14, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355876\" data-linked=\"RCI Hospitality Holdings up 2.3% due to stronger margins\" data-tweet=\"$RICK - RCI Hospitality Holdings up 2.3% due to stronger margins https://seekingalpha.com/news/3355876-rci-hospitality-holdings-up-2_3-due-to-stronger-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3355876-rci-hospitality-holdings-up-2_3-due-to-stronger-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355912\" data-ts=\"1526052687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBLN\" target=\"_blank\">OBLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355912-obalon-down-32-on-soft-q1-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obalon down 32% on soft Q1 sales</a></h4><ul><li>Thinly traded nano cap Obalon Therapeutics (<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a> <font color='red'>-31.5%</font>) slumps on more than a 4x surge in volume, albeit on turnover of only 277K shares, in response to its <a href=\"https://seekingalpha.com/pr/17160266-obalon-announces-first-quarter-2018-financial-results\" target=\"_blank\">Q1 results</a> that fell shy of consensus.</li><li>Revenues of $1.3M were down 13% despite the company's announcement of the highest number of treating accounts and treated patients in history.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355427-obalon-therapeutics-misses-0_21-misses-revenue\" target=\"_blank\">Obalon Therapeutics misses by $0.21, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355912\" data-linked=\"Obalon down 32% on soft Q1 sales\" data-tweet=\"$OBLN - Obalon down 32% on soft Q1 sales https://seekingalpha.com/news/3355912-obalon-down-32-on-soft-q1-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3355912-obalon-down-32-on-soft-q1-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355914\" data-ts=\"1526052684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLND\" target=\"_blank\">TLND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355914-talendminus-6-after-q1-rev-beat-in-line-and-better-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Talend -6% after Q1 rev beat, in-line and better guide</a></h4><ul><li>        Talend (NASDAQ:<a href='https://seekingalpha.com/symbol/TLND' title='Talend SA'>TLND</a>)&nbsp;<font color='red'>drops 6%</font>&nbsp;on Q1 results that beat revenue estimates with a 42% Y/Y growth and met on EPS.</li><li>               Q2 guidance has in-line revenue of $48.8M to $49.8M (consensus: $48.93M) and EPS of -$0.14 to -$0.11 (consensus: -$0.12).&nbsp;</li><li>               FY18 guidance has upside revenue of $202.6M to $204.6M (consensus: $201.51M) and EPS of -$0.49 to -$0.43 (consensus: -$0.46).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17160304-talend-reports-first-quarter-2018-financial-results\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355437-talend-eps-line-beats-revenue\" target=\"_blank\">Talend EPS in-line, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355914\" data-linked=\"Talend -6% after Q1 rev beat, in-line and better guide\" data-tweet=\"$TLND - Talend -6% after Q1 rev beat, in-line and better guide https://seekingalpha.com/news/3355914-talendminus-6-after-q1-rev-beat-in-line-and-better-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3355914-talendminus-6-after-q1-rev-beat-in-line-and-better-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355906\" data-ts=\"1526052126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRI\" target=\"_blank\">TRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355906-thomson-reutersminus-5-profits-revenues-fall-short-in-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thomson Reuters -5% as profits, revenues fall short in Q1</a></h4><ul>   <li>Thomson Reuters (NYSE:<a href='https://seekingalpha.com/symbol/TRI' title='Thomson Reuters Corporation'>TRI</a>) is <font color='red'>off 5%</font> after its best <a href=\"https://seekingalpha.com/news/3355731-thomson-reuters-reports-q1-results\" target=\"_blank\">Q1 earnings</a> in years still missed expectations, and despite a new buyback announcement.</li>    <li>On an IFRS basis, revenues grew 3.8% but were about 2.5% shy of consensus. And operating profit fell 2%, to $268M.</li>    <li>EBITDA rose 3% to $430M, beating an expected $394.8M.</li>    <li>The company also announced a new $500M share repurchase program.</li>    <li>Revenue breakout: Legal, $872M (up 4%; up 2% in constant currency); Tax &amp; Accounting, $437M (up 5%); Reuters news, $72M (down 3%; down 7% in constant currency).</li>    <li>EBITDA breakout: Legal, $319M (up 2%; up 1% in constant currency); Tax &amp; Accounting, $147M (up 4%; up 5% in constant currency); Reuters News, $8M (down 38%).</li>    <li>In initiating guidance for 2018, the company excluded its Financial &amp; Risk business (on its way to Blackstone) as a discontinued operation. It sees low-single-digit growth in revenues, adjusted EBITDA of $1.2B-$1.3B and total corporate costs of $500M-$600M (including stranded costs, and investments to reposition the company after the F&amp;R separation).</li>    <li><a href=\"https://seekingalpha.com/pr/17160774-thomson-reuters-reports-first-quarter-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3355906\" data-linked=\"Thomson Reuters -5% as profits, revenues fall short in Q1\" data-tweet=\"$TRI - Thomson Reuters -5% as profits, revenues fall short in Q1 https://seekingalpha.com/news/3355906-thomson-reutersminus-5-profits-revenues-fall-short-in-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3355906-thomson-reutersminus-5-profits-revenues-fall-short-in-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355905\" data-ts=\"1526052081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASYS\" target=\"_blank\">ASYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355905-amtech-systemsplus-16-on-q2-beats-downside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amtech Systems +16% on Q2 beats, downside guidance</a></h4><ul><li>           Amtech Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a>)&nbsp;<font color='green'>gains 16%</font>&nbsp;on Q2 results that beat EPS and revenue estimates. Downside Q3 guidance has revenue from $34M to $37M (consensus: $38.03M). </li><li> <a href=\"https://seekingalpha.com/news/3355469-amtech-eps-0_19\" target=\"_blank\">Press release. </a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3355469-amtech-eps-0_19\" target=\"_blank\">Amtech EPS of $0.19</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355905\" data-linked=\"Amtech Systems +16% on Q2 beats, downside guidance\" data-tweet=\"$ASYS - Amtech Systems +16% on Q2 beats, downside guidance https://seekingalpha.com/news/3355905-amtech-systemsplus-16-on-q2-beats-downside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3355905-amtech-systemsplus-16-on-q2-beats-downside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355896\" data-ts=\"1526051092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGR\" target=\"_blank\">RGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355896-algo-trading-active-on-unconfirmed-school-shooting-reports\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Algo trading active on unconfirmed school shooting reports</a></h4><ul> <li>Algo trading has picked up on very early reports of a possible school shooting in Palmdale, California.  Sturm Ruger (<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a> <font color='green'>+2.3%</font>), American Outdoor Brands (<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='green'>+3.2%</font>) and Vista Outdoor (<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='green'>+2.5%</font>) are the usual targets of the algorithmic trading based off of news searches and social media posts, rather than official police reports.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3355896\" data-linked=\"Algo trading active on unconfirmed school shooting reports\" data-tweet=\"$RGR $RGR $AOBC - Algo trading active on unconfirmed school shooting reports https://seekingalpha.com/news/3355896-algo-trading-active-on-unconfirmed-school-shooting-reports?source=tweet\" data-url=\"https://seekingalpha.com/news/3355896-algo-trading-active-on-unconfirmed-school-shooting-reports\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355893\" data-ts=\"1526050957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVA\" target=\"_blank\">SVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355893-sinovac-reports-strong-performance-in-h2-2017-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinovac reports strong performance in H2 2017; shares up 4%</a></h4><ul><li>Sinovac Biotech Ltd. (<a href='https://seekingalpha.com/symbol/SVA' title='Sinovac Biotech, Ltd.'>SVA</a> <font color='green'>+4.3%</font>) <a href=\"https://seekingalpha.com/pr/17161022-sinovac-files-2017-annual-report-form-20-f-reports-unaudited-second-half-audited-full-year\" target=\"_blank\">H2 results&nbsp;2017</a> ($M): Sales: 107.4 (+78.7%).</li><li>Net income: 18.7 (+405.4%); non-GAAP net income: 14.3 (+43.0%); EPS: 0.26 (+100.0%); non-GAAP EPS: 0.25 (+47.1%); cash flow ops: 56.3 (+999%).</li><li>About a month ago, the company received a communication from the SEC requesting documents related to certain shareholders and their affiliates, including 1Globe, the Chiang Li family and OrbiMed, to determine if anyone has violated U.S. securities laws. The company says it does not know it the company itself or its executives are under investigation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355893\" data-linked=\"Sinovac reports strong performance in H2 2017; shares up 4%\" data-tweet=\"$SVA - Sinovac reports strong performance in H2 2017; shares up 4% https://seekingalpha.com/news/3355893-sinovac-reports-strong-performance-in-h2-2017-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3355893-sinovac-reports-strong-performance-in-h2-2017-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355892\" data-ts=\"1526050829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKCA\" target=\"_blank\">AKCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355892-healthcare-top-5-gainers-losers-of-11-00-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (05/11/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/PRPH' title='ProPhase Labs, Inc.'>PRPH</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MYND' title='MYnd Analytics, Inc.'>MYND</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies Inc.'>SBOT</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='red'>-15%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355892\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (05/11/2018)\" data-tweet=\"$AKCA $AKCA $OMER - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (05/11/2018) https://seekingalpha.com/news/3355892-healthcare-top-5-gainers-losers-of-11-00-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355892-healthcare-top-5-gainers-losers-of-11-00-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355891\" data-ts=\"1526050796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUYA\" target=\"_blank\">HUYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355891-huya-opens-trading-from-ipo-shares-up-33\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huya opens trading from IPO; shares up 33%</a></h4><ul>   <li>Huya (NYSE:<a href='https://seekingalpha.com/symbol/HUYA' title='Huya Broadcasting'>HUYA</a>) -- the live videogame streaming unit of YY (<a href=\"http://seekingalpha.com/symbol/YY\" target=\"_blank\">YY</a> <font color='green'>+2.5%</font>) -- has opened trading at $15.50 and jumped to $15.95.</li>    <li>That's now <font color='green'>up about 33%</font> from its <a href=\"https://seekingalpha.com/news/3355727-huya-announces-pricing-initial-public-offering\" target=\"_blank\">IPO price of $12</a>.</li>    <li>Huya drew <a href=\"https://seekingalpha.com/news/3344540-yy-game-streaming-unit-huya-files-american-share-ipo\" target=\"_blank\">net revenues of $335.8M</a> in 2017, along with gross profit of $39.2M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355891\" data-linked=\"Huya opens trading from IPO; shares up 33%\" data-tweet=\"$HUYA $HUYA $YY - Huya opens trading from IPO; shares up 33% https://seekingalpha.com/news/3355891-huya-opens-trading-from-ipo-shares-up-33?source=tweet\" data-url=\"https://seekingalpha.com/news/3355891-huya-opens-trading-from-ipo-shares-up-33\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355887\" data-ts=\"1526049981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISR\" target=\"_blank\">ISR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355887-isoray-up-32-on-new-cesiumminus-131-stranding-device\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IsoRay up 32% on new Cesium-131 stranding device</a></h4><ul><li>Thinly traded nano cap IsoRay (<a href='https://seekingalpha.com/symbol/ISR' title='IsoRay, Inc.'>ISR</a> <font color='green'>+31.6%</font>) is up on a 16x surge in volume in response to the&nbsp;<a href=\"https://seekingalpha.com/pr/17160943-isoray-announces-first-disposable-delivery-system-custom-intra-operative-strands-prostate\" target=\"_blank\">announcement </a>of its Build-Blue disposable seed stranding device that will allow doctors to build custom-figured strands with Cesium-131 in the operating room for their prostate cancer patients.</li><li>The company says the device will enable it to enter the $25M U.S. intra-operative market for prostate brachytherapy. Commercial launch will commence this summer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355887\" data-linked=\"IsoRay up 32% on new Cesium-131 stranding device\" data-tweet=\"$ISR - IsoRay up 32% on new Cesium-131 stranding device https://seekingalpha.com/news/3355887-isoray-up-32-on-new-cesiumminus-131-stranding-device?source=tweet\" data-url=\"https://seekingalpha.com/news/3355887-isoray-up-32-on-new-cesiumminus-131-stranding-device\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355879\" data-ts=\"1526049299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCB\" target=\"_blank\">ARCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355879-arcbest-races-to-52-week-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcBest races to 52-week high</a></h4><ul> <li>ArcBest (<a href='https://seekingalpha.com/symbol/ARCB' title='ArcBest Corporation'>ARCB</a> <font color='green'>+16.8%</font>) soars after turning to an operating profit in Q1.</li> <li>\"Strong market demand for our supply chain solutions and purposeful yield management contributed to our positive first quarter results,\" says CEO Judy McReynolds.</li> <li>Shipments per day fell 9.4% during the quarter and tonnage per day were down 3.7%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355496-arcbest-beats-0_36-beats-revenue\" target=\"_blank\">ArcBest beats by $0.36, beats on revenue</a> (May 10)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3355879\" data-linked=\"ArcBest races to 52-week high\" data-tweet=\"$ARCB - ArcBest races to 52-week high https://seekingalpha.com/news/3355879-arcbest-races-to-52-week-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3355879-arcbest-races-to-52-week-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355872\" data-ts=\"1526048295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355872-dizzying-volatility-on-amira-nature-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dizzying volatility on Amira Nature Foods</a></h4><ul> <li>Amira Nature Foods (<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+62.4%</font>) is skyrocketing after hitting a record low yesterday of $1.62 on a 49% drop.</li> <li>Jefferies is out with a full defense on Amira, saying FQ3 results show \"continued sequential acceleration\" in revenue and EBITDA growth. The firm sets a price target of $6.</li> <li>The 52-week high on ANFI is $7.05.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3355872\" data-linked=\"Dizzying volatility on Amira Nature Foods\" data-tweet=\"$ANFI - Dizzying volatility on Amira Nature Foods https://seekingalpha.com/news/3355872-dizzying-volatility-on-amira-nature-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3355872-dizzying-volatility-on-amira-nature-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355871\" data-ts=\"1526048107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355871-analyst-raise-nvidias-price-targets-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst raise Nvidia&#39;s price targets after earnings</a></h4><ul><li>        Goldman Sachs <a href=\"https://www.cnbc.com/2018/05/11/wall-street-still-loves-nvidia-despite-chipmakers-prediction-of-plunging-crypto-mining-sales.html\" target=\"_blank\">reiterates</a> its Buy rating for Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) and raises the price target from $275 to $310, a 19% upside to yesterday&rsquo;s close.</li><li>               Analyst Toshiya Hari notes that Nvidia expects cryptocurrency-related revenue to decline significantly in Q2 based on customer feedback.&nbsp;</li><li>               Hari: &ldquo;With crypto now de-risked, in our view, the new product launch in Gaming ahead of us, we see positive risk-reward and would thus recommend investors to Buy the stock.&rdquo;&nbsp;</li><li>               More action: Bank of America Merrill Lynch raises its Nvidia target from $300 to $340 and reiterates a Buy rating.&nbsp;</li><li>               Analyst Vivek Arya says the company&rsquo;s &ldquo;leadership in AI remains the most critical component of stock sentiment/valuation.&rdquo;&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='red'>down 1.8%</font>&nbsp;to $255.54. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355550-nvidia-minus-1_7-percent-q1-beats-upside-guide-strength-gaming-datacenter\" target=\"_blank\">Nvidia -1.7% after Q1 beats, upside guide, strength in Gaming and Datacenter</a> (May 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355777-nvidia-earnings-call-gpu-pricing-crypto-demand-tams\" target=\"_blank\">Nvidia earnings call: GPU pricing, crypto demand, and TAMs</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355871\" data-linked=\"Analyst raise Nvidia&#39;s price targets after earnings\" data-tweet=\"$NVDA - Analyst raise Nvidia&#39;s price targets after earnings https://seekingalpha.com/news/3355871-analyst-raise-nvidias-price-targets-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3355871-analyst-raise-nvidias-price-targets-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355870\" data-ts=\"1526048010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SATS\" target=\"_blank\">SATS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355870-echostarplus-4_6-raymond-james-boosts-to-strong-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EchoStar +4.6% as Raymond James boosts to Strong Buy</a></h4><ul>   <li>EchoStar (NASDAQ:<a href='https://seekingalpha.com/symbol/SATS' title='EchoStar Corporation'>SATS</a>) is <font color='green'>up 4.6%</font> after an upgrade to Strong Buy at Raymond James, from Outperform.</li>    <li>The firm bumped its price target to $75 from $74, implying 38.3% upside from the now-higher current price.</li>    <li>Shares are <font color='green'>up 38%</font> since Sept. 1; they're <font color='green'>up 4.8%</font> in 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355870\" data-linked=\"EchoStar +4.6% as Raymond James boosts to Strong Buy\" data-tweet=\"$SATS - EchoStar +4.6% as Raymond James boosts to Strong Buy https://seekingalpha.com/news/3355870-echostarplus-4_6-raymond-james-boosts-to-strong-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3355870-echostarplus-4_6-raymond-james-boosts-to-strong-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355869\" data-ts=\"1526047903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RRC\" target=\"_blank\">RRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355869-range-resources-shareholder-plans-to-vote-against-board-nominees\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Range Resources shareholder plans to vote against board nominees</a></h4><ul>     <li>Range Resources (<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-1.9%</font>) shareholder Stelliam Management sends a letter indicating its intention to <a href=\"https://seekingalpha.com/pr/17160505-stelliam-sends-letter-range-resources-board\" target=\"_blank\">vote against</a> the company&rsquo;s board nominees and executive compensation at next week's annual meeting.</li>     <li>\"We believe compensation should be tied to performance, not who sits in a particular seat,\" Stelliam says. \"Regarding this point, management&rsquo;s annual compensation has remained generous over the past four years while the stock has declined approximately 80%.\"</li>     <li>Stelliam notes \"the systemic annual awarding of increasing numbers of shares at successively lower prices to the management and board.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355869\" data-linked=\"Range Resources shareholder plans to vote against board nominees\" data-tweet=\"$RRC - Range Resources shareholder plans to vote against board nominees https://seekingalpha.com/news/3355869-range-resources-shareholder-plans-to-vote-against-board-nominees?source=tweet\" data-url=\"https://seekingalpha.com/news/3355869-range-resources-shareholder-plans-to-vote-against-board-nominees\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355866\" data-ts=\"1526047123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDFN\" target=\"_blank\">RDFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355866-redfinminus-4_7-on-q1-rev-beat-in-line-guide-weak-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Redfin -4.7% on Q1 rev beat, in-line guide, weak margins</a></h4><ul><li>        Redfin (NASDAQ:<a href='https://seekingalpha.com/symbol/RDFN' title='Redfin'>RDFN</a>)&nbsp;<font color='red'>falls 4.7%</font>&nbsp;after yesterday&rsquo;s Q1 report beat revenue estimates with a 33% Y/Y growth and met EPS estimates. In-line Q2 guidance has revenue of $134.8M to $139.1M (consensus: $134.49M) with Redfin Now revenue of $5.2M to $6.2M.</li><li>               Margin weakness: Gross margin was 7% (-4 pts Y/Y) with real estate gross margin at 9% (-3 pts).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17160264-redfin-first-quarter-2018-revenue-33-percent-year-year-79_9-million\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355415-redfin-eps-line-beats-revenue\" target=\"_blank\">Redfin EPS in-line, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355866\" data-linked=\"Redfin -4.7% on Q1 rev beat, in-line guide, weak margins\" data-tweet=\"$RDFN - Redfin -4.7% on Q1 rev beat, in-line guide, weak margins https://seekingalpha.com/news/3355866-redfinminus-4_7-on-q1-rev-beat-in-line-guide-weak-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3355866-redfinminus-4_7-on-q1-rev-beat-in-line-guide-weak-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355864\" data-ts=\"1526046972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355864-cytrx-down-30-on-direct-placement-of-stock-1_25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx down 30% on direct placement of stock at $1.25</a></h4><ul><li>CytRx (<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-29.6%</font>) is down on almost triple normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/17160873-cytrx-announces-7_0-million-registered-direct-offering\" target=\"_blank\">deal with institutional investors </a>to sell 5.6M shares of common stock at $1.25 per share. Gross proceeds will be $7M. Closing date is May 15.</li><li>Yesterday's close was $1.89.</li><li><strong>Update</strong>: On May 15, the company <a href=\"https://seekingalpha.com/pr/17164781-cytrx-announces-closing-7_0-million-registered-direct-offering\" target=\"_blank\">announced </a>the closing of the offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355864\" data-linked=\"CytRx down 30% on direct placement of stock at $1.25\" data-tweet=\"$CYTR - CytRx down 30% on direct placement of stock at $1.25 https://seekingalpha.com/news/3355864-cytrx-down-30-on-direct-placement-of-stock-1_25?source=tweet\" data-url=\"https://seekingalpha.com/news/3355864-cytrx-down-30-on-direct-placement-of-stock-1_25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355857\" data-ts=\"1526045420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355857-canaccord-raises-dropbox-target-calls-pullback-buying-opportunity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canaccord raises Dropbox target, calls pullback a buying opportunity</a></h4><ul><li>        Canaccord Genuity raises its Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a>) target by a dollar to $36 after the earnings report.</li><li>               The firm says the market&rsquo;s reaction &ldquo;reminds us of the recent silliness in which fretting about Atlassian&rsquo;s quarter led to a dip to which savvy investors said, &lsquo;Thank you very much.' And gobbled up shares from weak hands.&rdquo;&nbsp;&nbsp;</li><li>        Canaccord says with Dropbox it has &ldquo;absolutely zero hesitation recommending purchase of the shares today.&rdquo;</li><li>               Dropbox shares are&nbsp;<font color='red'>down 0.2%</font>&nbsp;premarket to $31.94.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355500-dropboxs-first-earnings-report-beats-estimates\" target=\"_blank\">Dropbox's first earnings report beats estimates</a> (May 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355773-dropbox-reveals-upside-guidance-earnings-call-shares-minus-2_8-percent\" target=\"_blank\">Dropbox reveals upside guidance on earnings call; shares -2.8%</a> (May 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355857\" data-linked=\"Canaccord raises Dropbox target, calls pullback a buying opportunity\" data-tweet=\"$DBX - Canaccord raises Dropbox target, calls pullback a buying opportunity https://seekingalpha.com/news/3355857-canaccord-raises-dropbox-target-calls-pullback-buying-opportunity?source=tweet\" data-url=\"https://seekingalpha.com/news/3355857-canaccord-raises-dropbox-target-calls-pullback-buying-opportunity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355854\" data-ts=\"1526045203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VZ\" target=\"_blank\">VZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355854-verizonplus-1_8-jpmorgan-boosts-to-overweight-on-5g\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verizon +1.8% as JPMorgan boosts to Overweight on 5G</a></h4><ul>   <li>Verizon (NYSE:<a href='https://seekingalpha.com/symbol/VZ' title='Verizon Communications'>VZ</a>) is <font color='green'>up 1.8%</font> premarket as JPMorgan upgrades to Overweight ahead of the early stirrings of 5G deployment.</li>    <li>A meeting with CEO Lowell McAdam has prompted analyst Philip Cusic to write that the \"5G opportunity will start to crystallize in the next few months,\" with early cash flow coming more from Verizon's potential for a fixed broadband offering than from handsets that won't be a near-term game-changer. (h/t Bloomberg)</li>    <li>Cusic has a price target of $58, implying 22.9% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355854\" data-linked=\"Verizon +1.8% as JPMorgan boosts to Overweight on 5G\" data-tweet=\"$VZ - Verizon +1.8% as JPMorgan boosts to Overweight on 5G https://seekingalpha.com/news/3355854-verizonplus-1_8-jpmorgan-boosts-to-overweight-on-5g?source=tweet\" data-url=\"https://seekingalpha.com/news/3355854-verizonplus-1_8-jpmorgan-boosts-to-overweight-on-5g\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355850\" data-ts=\"1526045009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355850-kitov-inks-commercialization-deal-for-consensi-in-china-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov inks commercialization deal for Consensi in China; shares up 7% premarket</a></h4><ul><li>Thinly traded nano cap Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17160939-kitov-announces-consensi-commercialization-agreement-china\" target=\"_blank\">agreement </a>with Hebei Changshan Biochemical Pharmaceutical Co., Ltd. granting the latter exclusive rights to import, manufacture and distribute lead drug Consensi (formerly KIT-302) in China, Taiwan, Hong Kong and Macau.</li><li>Under the terms of the deal, Kitov will receive $3.5M upon U.S. approval of Consensi (FDA action date May 31) and the achievement of Chinese regulatory milestones (should be approval), up to $6M in commercial milestones and 12% royalties on net sales.</li><li>Changshan Pharma will be responsible for financing and regulatory approval from the CFDA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355850\" data-linked=\"Kitov inks commercialization deal for Consensi in China; shares up 7% premarket\" data-tweet=\"$KTOV - Kitov inks commercialization deal for Consensi in China; shares up 7% premarket https://seekingalpha.com/news/3355850-kitov-inks-commercialization-deal-for-consensi-in-china-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3355850-kitov-inks-commercialization-deal-for-consensi-in-china-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355845\" data-ts=\"1526044890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355845-cytrx-announces-7m-registered-direct-offering-shares-down-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx announces $7M registered direct offering; shares down 28% premarket</a></h4><ul> <li>CytRx Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a>) has <a href=\"https://seekingalpha.com/pr/17160873-cytrx-announces-7_0-million-registered-direct-offering\" target=\"_blank\">entered</a> into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 5.6M shares of its common stock, at a purchase price of $1.25 per share.</li><li>Closing date is May 15.</li>  <li>Expected net proceeds of ~$6.5M will be used for working capital and general corporate purposes.</li><li>Shares are down&nbsp;<font color='red'>28%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355845\" data-linked=\"CytRx announces $7M registered direct offering; shares down 28% premarket\" data-tweet=\"$CYTR - CytRx announces $7M registered direct offering; shares down 28% premarket https://seekingalpha.com/news/3355845-cytrx-announces-7m-registered-direct-offering-shares-down-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3355845-cytrx-announces-7m-registered-direct-offering-shares-down-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355844\" data-ts=\"1526044773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOSY\" target=\"_blank\">MOSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355844-premarket-gainers-of-9-05-05-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (05/11/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='green'>+47%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3355463-mosys-beats-0_10-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+32%</font>.</li><li><a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a> <font color='green'>+29%</font>&nbsp;on Q1&nbsp;result</a>.</li><li><a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a> <font color='green'>+14%</font>&nbsp;on Q1&nbsp;<a href=\"https://seekingalpha.com/news/3355512-immersion-beats-0_99-beats-revenue\" target=\"_blank\">result</a>.</li><li>RXII <font color='green'>+14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355771-rxi-pharmaceuticals-inks-deal-iovance-biotherapeutics-study-rnai-technology-advancement\" target=\"_blank\">entering</a>&nbsp;into a research collaboration with Iovance Biotherapeutics.</li><li><a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+12%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3355760-viewray-files-150m-mixed-shelf-offering\" target=\"_blank\">filing</a> for $150M mixed shelf offering.</li><li><a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+8%</font>. on commercialization <a href=\"https://seekingalpha.com/pr/17160939-kitov-announces-consensi-commercialization-agreement-china\" target=\"_blank\">agreement</a>.</li><li><a href='https://seekingalpha.com/symbol/ATTU' title='Attunity Ltd'>ATTU</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355844\" data-linked=\"Premarket Gainers as of 9:05 am (05/11/2018)\" data-tweet=\"$MOSY $MOSY $ANFI - Premarket Gainers as of 9:05 am (05/11/2018) https://seekingalpha.com/news/3355844-premarket-gainers-of-9-05-05-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355844-premarket-gainers-of-9-05-05-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355842\" data-ts=\"1526044463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBOT\" target=\"_blank\">SBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355842-premarket-losers-of-9-05-5-11-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (5/11/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies Inc.'>SBOT</a>&nbsp;<font color='red'>-41%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355743-stellar-bio-prices-equity-offering-shares-38-percent-premarket\" target=\"_blank\">pricing</a> equity offering.</li><li><a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>&nbsp;<font color='red'>-30%</font>&nbsp;on downside guidance and <a href=\"https://seekingalpha.com/news/3355568-symantec-minus-13_2-percent-q4-beats-downside-guides-internal-investigation\" target=\"_blank\">internal investigation</a>.</li><li><a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>CYTR</a> <font color='red'>-29%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17160873-cytrx-announces-7_0-million-registered-direct-offering\" target=\"_blank\">announcing</a> direct offering.</li><li><a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355493-synergy-pharma-beats-0_01-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355433-halozyme-therapeutics-beats-0_03-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355424-ziopharm-oncology-misses-0_02\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355446-intrexon-misses-0_09-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3355827-rough-run-cryptos-gets-worse\" target=\"_blank\">Bitcoin</a> plunge.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3355842\" data-linked=\"Premarket Losers as of 9:05 am (5/11/2018)\" data-tweet=\"$SBOT $EDSA $NLOK - Premarket Losers as of 9:05 am (5/11/2018) https://seekingalpha.com/news/3355842-premarket-losers-of-9-05-5-11-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3355842-premarket-losers-of-9-05-5-11-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355840\" data-ts=\"1526044256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355840-intrexon-down-9-premarket-after-q1-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon down 9% premarket after Q1 miss</a></h4><ul><li>Intrexon (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <a href=\"https://seekingalpha.com/pr/17160351-intrexon-announces-first-quarter-2018-financial-results\" target=\"_blank\">Q1 results</a> ($M): Revenues: 43.8 (-18.4%); Collaborations &amp; Licensing: 24.1 (-27.2%). Decrease due to drop in R&amp;D services for certain collaborators.</li><li>Net loss: (42.0) (-29.6%).</li><li>Shares are down&nbsp;<font color='red'>9%</font>&nbsp;premarket on modest volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355446-intrexon-misses-0_09-misses-revenue\" target=\"_blank\">Intrexon misses by $0.09, misses on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355840\" data-linked=\"Intrexon down 9% premarket after Q1 miss\" data-tweet=\"$XON - Intrexon down 9% premarket after Q1 miss https://seekingalpha.com/news/3355840-intrexon-down-9-premarket-after-q1-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3355840-intrexon-down-9-premarket-after-q1-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355827\" data-ts=\"1526043184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTC-USD\" target=\"_blank\">BTC-USD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355827-rough-run-for-cryptos-gets-worse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough run for cryptos gets worse</a></h4><ul><li>Threatening $10K as we headed into last weekend, bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) is lower by&nbsp;<font color='red'>more than 5%</font>&nbsp;today, and down to $8.5K.</li><li>Also plunging today are Ethereum (<a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>)<font color='red'> down 6.5%</font>, Ripple (<a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>)&nbsp;<font color='red'>down 11.5%</font>, Bitcoin Cash (<a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a>)&nbsp;<font color='red'>down 11%</font>, and EOS (<a href='https://seekingalpha.com/symbol/EOS-USD' title='EOS USD'>EOS-USD</a>)&nbsp;<font color='red'>down 15%</font>, and Litecoin (<a href='https://seekingalpha.com/symbol/LTC-USD' title='Litecoin USD'>LTC-USD</a>)&nbsp;<font color='red'>down 6.7%</font>.</li><li>In the latest FUD, South Korean prosecutors <a href=\"https://www.bloomberg.com/news/articles/2018-05-11/cryptocurrency-exchange-upbit-raided-by-south-korean-authorities?utm_campaign=socialflow-organic&amp;utm_source=twitter&amp;utm_content=crypto&amp;utm_medium=social\" target=\"_blank\">this morning raided</a> the offices of Upbit, one of the globe's top-five busiest crypto exchanges. The exchange - on which about $1.6B in trades took place in the last 24 hours - says all client assets are safe, and transactions and withdrawals are unaffected.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>, <a href='https://seekingalpha.com/symbol/ETH-USD' title='Ethereum USD'>ETH-USD</a>, <a href='https://seekingalpha.com/symbol/XRP-USD' title='XRP USD'>XRP-USD</a>, <a href='https://seekingalpha.com/symbol/BCH-USD' title='Bitcoin Cash USD'>BCH-USD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3355827\" data-linked=\"Rough run for cryptos gets worse\" data-tweet=\"$BTC-USD $BTC-USD $ETH-USD - Rough run for cryptos gets worse https://seekingalpha.com/news/3355827-rough-run-for-cryptos-gets-worse?source=tweet\" data-url=\"https://seekingalpha.com/news/3355827-rough-run-for-cryptos-gets-worse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355825\" data-ts=\"1526043095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355825-eyegate-up-6-on-q1-result\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eyegate up 6% on Q1 result</a></h4><ul><li>Eyegate Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a>) <a href=\"https://seekingalpha.com/filing/4019077\" target=\"_blank\">Q1 results</a>: Revenues: $1.1M; R&amp;D Expense: $2.5M (+38.9%); SG&amp;A: $1M (-23.1%); Net Loss: ($2.4M) (+17.2%); Loss Per Share: ($0.14) (+50.0%); Quick Assets: $3.6M (-53.8%); CF Ops: ($4.1M).</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355825\" data-linked=\"Eyegate up 6% on Q1 result\" data-tweet=\"$EYEG - Eyegate up 6% on Q1 result https://seekingalpha.com/news/3355825-eyegate-up-6-on-q1-result?source=tweet\" data-url=\"https://seekingalpha.com/news/3355825-eyegate-up-6-on-q1-result\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355817\" data-ts=\"1526042217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355817-astrazenecas-benralizumab-flunks-late-stage-copd-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s benralizumab flunks late-stage COPD study</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html\" target=\"_blank\">announces </a>that a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02138916?intr=Benralizumab&amp;titles=galathea&amp;rank=1\" target=\"_blank\">GALATHEA</a>, evaluating asthma med <a href=\"https://www.fasenra.com/?source=BEN_D_C_2&amp;umedium=CPC&amp;uadpub=Google&amp;ucampaign=FasenraDTCBranded_General&amp;ucreative=Alone_EX&amp;uplace=fasenra&amp;cmpid=1\" target=\"_blank\">Fasenra </a>(benralizumab) in patients with moderate-to-severe chronic obstructive pulmonary disease &#40;COPD&#41; failed to demonstrate a statistically valid decrease in exacerbations, the primary endpoint.</li><li>The company says it will assess the next steps after it receives the results from the second Phase 3 study called <a href=\"https://clinicaltrials.gov/ct2/show/NCT02155660?titles=terranova&amp;rank=1\" target=\"_blank\">TERRANOVA</a>.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355817\" data-linked=\"AstraZeneca&#39;s benralizumab flunks late-stage COPD study\" data-tweet=\"$AZN - AstraZeneca&#39;s benralizumab flunks late-stage COPD study https://seekingalpha.com/news/3355817-astrazenecas-benralizumab-flunks-late-stage-copd-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3355817-astrazenecas-benralizumab-flunks-late-stage-copd-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355816\" data-ts=\"1526042151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355816-eyegate-pharmaceuticals-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eyegate Pharmaceuticals reports Q1 results</a></h4><ul><li>Eyegate Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a>): Q1 net loss of $2.38M</li><li>Revenue of $1.1M</li><li>Shares <font color='green'>+5.64%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17160911-eyegate-pharmaceuticals-reports-first-quarter-2018-financial-results-provides-business-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3355816\" data-linked=\"Eyegate Pharmaceuticals reports Q1 results\" data-tweet=\"$EYEG - Eyegate Pharmaceuticals reports Q1 results https://seekingalpha.com/news/3355816-eyegate-pharmaceuticals-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355816-eyegate-pharmaceuticals-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355806\" data-ts=\"1526041967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355806-celsion-net-loss-improves-in-q1-shares-ahead-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion net loss improves in Q1; shares ahead 14% premarket</a></h4><ul><li>Celsion (<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>) <a href=\"https://seekingalpha.com/pr/17160871-celsion-corporation-reports-first-quarter-2018-financial-results-provides-business-update\" target=\"_blank\">Q1 results</a>: Revenues: $0.1M (unch); Operating Loss: ($4.3M) (+10.4%); Net Loss: ($4.5M) (+13.5%); Loss Per Share: ($0.25) (+91.9%); Quick Assets: $2.3M (-79.8%).</li><li><strong>Business update</strong>: The Company is well positioned to complete enrollment in its ongoing 550 patient global, Phase III OPTIMA Study in primary liver cancer and plans to initiate its 130 patient Phase I/II randomized OVATION II Study in newly diagnosed patients with ovarian cancer in June 2018 and reporting clinical findings from the Phase I cohort of 12 patients of the OVATION II by the end of 2018.</li><li>The Company expects to report final progression-free survival data from our Phase IB clinical trial (the OVATION I Study) by the end of Q2 2018.</li><li>Shares are up&nbsp;<font color='green'>14%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355806\" data-linked=\"Celsion net loss improves in Q1; shares ahead 14% premarket\" data-tweet=\"$CLSN - Celsion net loss improves in Q1; shares ahead 14% premarket https://seekingalpha.com/news/3355806-celsion-net-loss-improves-in-q1-shares-ahead-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3355806-celsion-net-loss-improves-in-q1-shares-ahead-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355811\" data-ts=\"1526041845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IQ\" target=\"_blank\">IQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355811-iqiyiplus-3_8-on-drm-approval-in-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IQiyi +3.8% on DRM approval in China</a></h4><ul><li>        IQiyi (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc'>IQ</a>) announces that its DRM system was approved by ChinaDRM Lab, the first approval for a domestic internet video platform.</li><li>               ChinaDRM Lab is a subdivision of the Academy of Broadcasting Science of China.&nbsp;</li><li>                  IQ shares are&nbsp;<font color='green'>up 3.8%</font>&nbsp;premarket to $21.50. </li></ul><div class=\"tiny-share-widget\" data-id=\"3355811\" data-linked=\"IQiyi +3.8% on DRM approval in China\" data-tweet=\"$IQ - IQiyi +3.8% on DRM approval in China https://seekingalpha.com/news/3355811-iqiyiplus-3_8-on-drm-approval-in-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3355811-iqiyiplus-3_8-on-drm-approval-in-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355808\" data-ts=\"1526041689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPRT\" target=\"_blank\">WPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355808-westport-fuelplus-3-q1-loss-edges-lower-year-ago\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westport Fuel +3% as Q1 loss edges lower than a year ago</a></h4><ul>     <li>Westport Fuel Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a>)&nbsp;<font color='green'>+3.1%</font> premarket after reporting a <a href=\"https://seekingalpha.com/news/3355676-westport-innovations-eps-line-beats-revenue\" target=\"_blank\">Q1 loss</a> that met expectations and was smaller than the $0.12/share loss in the year-ago quarter, while revenues rose 12% Y/Y to a higher than expected $67.6M.</li>     <li>Q1 gross margin fell 13% Y/Y to $15.3M, which the company attributes to lower service revenues and the ramp-up of the Westport HPDI 2.0 product.</li>     <li>WPRT issues in-line guidance for FY 2018 revenues of $255M-$275M, up 3%-11% Y/Y, and expects to achieve positive adjusted EBITDA during Q2, driven by continued reduction in R&amp;D expenses and CWI performance.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355808\" data-linked=\"Westport Fuel +3% as Q1 loss edges lower than a year ago\" data-tweet=\"$WPRT - Westport Fuel +3% as Q1 loss edges lower than a year ago https://seekingalpha.com/news/3355808-westport-fuelplus-3-q1-loss-edges-lower-year-ago?source=tweet\" data-url=\"https://seekingalpha.com/news/3355808-westport-fuelplus-3-q1-loss-edges-lower-year-ago\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355804\" data-ts=\"1526041264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSCT\" target=\"_blank\">FSCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355804-forescout-technologiesplus-7_3-on-q1-beats-upside-q2-and-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ForeScout Technologies +7.3% on Q1 beats, upside Q2 and FY guidance</a></h4><ul><li>        ForeScout Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/FSCT' title='ForeScout Technologies, Inc.'>FSCT</a>)&nbsp;<font color='green'>gains 7.3%</font>&nbsp;premarket on Q1 results that beat EPS and revenue estimates with a 42% Y/Y revenue growth.</li><li>                  Upside Q2 guidance has revenue form $61M to $64M (consensus: $59.39M) and EPS of -$0.39 to -$0.37 (consensus: -$0.41).    </li><li>               Upside FY18 guidance has revenue of $270M to $280.4M (consensus: $269.14M) with EPS from -$1.08 to -$1.00 (consensus: -$1.10).&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17160385-forescout-technologies-reports-strong-first-quarter-2018-financial-results\" target=\"_blank\">Press release</a>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355486-forescout-technologies-beats-0_07-beats-revenue\" target=\"_blank\">ForeScout Technologies beats by $0.07, beats on revenue</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355804\" data-linked=\"ForeScout Technologies +7.3% on Q1 beats, upside Q2 and FY guidance\" data-tweet=\"$FSCT - ForeScout Technologies +7.3% on Q1 beats, upside Q2 and FY guidance https://seekingalpha.com/news/3355804-forescout-technologiesplus-7_3-on-q1-beats-upside-q2-and-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3355804-forescout-technologiesplus-7_3-on-q1-beats-upside-q2-and-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355803\" data-ts=\"1526041240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GERN\" target=\"_blank\">GERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355803-geron-down-8-premarket-after-q1-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Geron down 8% premarket after Q1 report</a></h4><ul><li>Geron (NASDAQ:<a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a>) <a href=\"https://seekingalpha.com/pr/17160378-geron-corporation-reports-first-quarter-2018-financial-results\" target=\"_blank\">Q1 results</a> ($M): Revenues from licence fees &amp; royalties: 0.3 (-40.8%); Net loss: (7.2) (flat).</li><li>The company confirms that it experienced a reduction in the number of active non-imetelstat license agreements and decreased sales from licensees, but adds that it adopted a new accounting treatment for revenue called a modified retrospective transition method. Historical results were reported under its previous accounting method so the results are not comparable.</li><li>Shares are down&nbsp;<font color='red'>8%</font>&nbsp;premarket on modest volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355472-geron-beats-0_01\" target=\"_blank\">Geron beats by $0.01</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355803\" data-linked=\"Geron down 8% premarket after Q1 report\" data-tweet=\"$GERN - Geron down 8% premarket after Q1 report https://seekingalpha.com/news/3355803-geron-down-8-premarket-after-q1-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3355803-geron-down-8-premarket-after-q1-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>115&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355800\" data-ts=\"1526040975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355800-neutral-feeling-on-kroger-from-wall-street\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neutral feeling on Kroger from Wall Street</a></h4><ul> <li>MoffettNathanson lowers Kroger (NYSE:<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a>) to a Neutral rating after having the grocery stock set at Buy. There are now more Neutral/Hold equivalent ratings from Wall Street analysts on Kroger than Buys.</li> <li>The investment firm's price target of $27 reps 11% downside potential for shares.</li> <li>Kroger is <font color='red'>down 0.37%</font> in premarket trading to $24.26 vs. a 52-week trading range of $19.69 to $31.45.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3355800\" data-linked=\"Neutral feeling on Kroger from Wall Street\" data-tweet=\"$KR - Neutral feeling on Kroger from Wall Street https://seekingalpha.com/news/3355800-neutral-feeling-on-kroger-from-wall-street?source=tweet\" data-url=\"https://seekingalpha.com/news/3355800-neutral-feeling-on-kroger-from-wall-street\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355795\" data-ts=\"1526040521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MT\" target=\"_blank\">MT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355795-arcelormittalplus-2_5-after-q1-profit-surge-optimistic-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArcelorMittal +2.5% after Q1 profit surge, optimistic outlook</a></h4><ul>     <li>ArcelorMittal (NYSE:<a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a>)&nbsp;<font color='green'>+2.5%</font> premarket after reporting <a href=\"https://seekingalpha.com/news/3355716-arcelormittal-reports-q1-results\" target=\"_blank\">Q1 net profit</a> of $1.19B compared with $1B in the year-ago quarter, while sales jumped 16% to $19.2B, both figures coming in <a href=\"https://www.wsj.com/articles/arcelormittal-1st-quarter-profit-supported-by-strong-steel-prices-1526016507?mod=yahoo_hs&amp;yptr=yahoo\" target=\"_blank\">well ahead of analyst estimates</a>.</li>     <li>Q1 EBITDA rose 13% Y/Y to $2.51B, above company guidance of $2.32B, reflecting higher average steel selling prices and higher seaborne iron ore reference prices.</li>     <li>MT's average steel selling price during Q1 was 18.2% higher than in the same quarter of 2017, with shipments up 1.4%; iron ore shipments rose 5.5% Y/Y while prices were down 13.1%.</li>     <li>MT says it expects market conditions to remain favorable but does not upgrade guidance for the year; it reaffirms its outlook for 2018 global apparent steel consumption rising 1.5%-2.5%.</li>     <li>&ldquo;The first quarter was better than expected and the market backdrop for the second and third quarters is better than we imagined at the start of the year. It&rsquo;s improving almost on a week-by-week basis,&rdquo; <a href=\"https://www.reuters.com/article/us-arcelormittal-results/arcelormittal-gives-bullish-outlook-after-earnings-beat-idUSKBN1IC0D7\" target=\"_blank\">says</a> Commerzbank analyst Ingo Martin Schachel.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355795\" data-linked=\"ArcelorMittal +2.5% after Q1 profit surge, optimistic outlook\" data-tweet=\"$MT - ArcelorMittal +2.5% after Q1 profit surge, optimistic outlook https://seekingalpha.com/news/3355795-arcelormittalplus-2_5-after-q1-profit-surge-optimistic-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3355795-arcelormittalplus-2_5-after-q1-profit-surge-optimistic-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355794\" data-ts=\"1526040492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355794-ionis-and-akcea-up-premarket-after-ad-com-vote\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis and Akcea up premarket after Ad Com vote</a></h4><ul><li>Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) and affiliate Akcea Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKCA' title='Akcea Therapeutics'>AKCA</a>) are up&nbsp;<font color='green'>3%</font>&nbsp;and&nbsp;<font color='green'>16%</font>, respectively, in light premarket trade after an FDA Ad Com voted 12 - 8 backing volanesorsen, branded as WAYLIVRA, for familial chylomicronemia syndrome.</li><li>The FDA's action date is August 30.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355400-fda-ad-com-renders-split-vote-akceas-volanesoren\" target=\"_blank\">FDA Ad Com renders split vote on Akcea's volanesoren</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355794\" data-linked=\"Ionis and Akcea up premarket after Ad Com vote\" data-tweet=\"$IONS $IONS $AKCA - Ionis and Akcea up premarket after Ad Com vote https://seekingalpha.com/news/3355794-ionis-and-akcea-up-premarket-after-ad-com-vote?source=tweet\" data-url=\"https://seekingalpha.com/news/3355794-ionis-and-akcea-up-premarket-after-ad-com-vote\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355787\" data-ts=\"1526040205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355787-synergy-pharma-down-10-premarket-on-soft-trulance-sales-in-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharma down 10% premarket on soft Trulance sales in Q1</a></h4><ul><li>Synergy Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a>) <a href=\"https://seekingalpha.com/pr/17160419-synergy-pharmaceuticals-reports-first-quarter-2018-financial-results-business-update\" target=\"_blank\">Q1 results</a> ($M):&nbsp;TRULANCE sales:&nbsp;8.6M (-8.5% sequentially). Sales were up 16.9% sequentially based on the recognition of deferred sales of $2.1M as of September 30, 2017.</li><li>Net loss: (36.1) (+44.1%).</li><li><strong>2018 Guidance</strong>: Operating expenses: $165M - 175M from $175M - 185M.</li><li>Review of strategic alternatives ongoing.</li><li>Shares are down&nbsp;<font color='red'>10%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355787\" data-linked=\"Synergy Pharma down 10% premarket on soft Trulance sales in Q1\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharma down 10% premarket on soft Trulance sales in Q1 https://seekingalpha.com/news/3355787-synergy-pharma-down-10-premarket-on-soft-trulance-sales-in-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3355787-synergy-pharma-down-10-premarket-on-soft-trulance-sales-in-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355784\" data-ts=\"1526040116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355784-celsion-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion reports Q1 results</a></h4><ul><li>Celsion (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>): Q1 EPS of -$0.25</li><li>Revenue of $0.13M (flat Y/Y)</li><li>Shares <font color='green'>+1.77%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17160871-celsion-corporation-reports-first-quarter-2018-financial-results-provides-business-update'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3355784\" data-linked=\"Celsion reports Q1 results\" data-tweet=\"$CLSN - Celsion reports Q1 results https://seekingalpha.com/news/3355784-celsion-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3355784-celsion-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355779\" data-ts=\"1526039658\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVID\" target=\"_blank\">AVID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355779-avid-techplus-1_2-despite-q1-revenue-miss-in-line-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avid Tech +1.2% despite Q1 revenue miss, in-line guide</a></h4><ul><li>        Avid Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/AVID' title='Avid Technology, Inc.'>AVID</a>) reports Q1 results that miss revenue estimates with a 6% Y/Y drop in revenue. In-line Q2 guidance has revenue of $97M to $107M (consensus: $99.57M).</li><li>               <a href=\"https://seekingalpha.com/pr/17160447-avid-technology-announces-q1-2018-results-issues-q2-2018-guidance\" target=\"_blank\">Press release</a>.&nbsp;</li><li>               Avid shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $4.95. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355499-avid-eps-0_22\" target=\"_blank\">Avid EPS of -$0.22</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355779\" data-linked=\"Avid Tech +1.2% despite Q1 revenue miss, in-line guide\" data-tweet=\"$AVID - Avid Tech +1.2% despite Q1 revenue miss, in-line guide https://seekingalpha.com/news/3355779-avid-techplus-1_2-despite-q1-revenue-miss-in-line-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3355779-avid-techplus-1_2-despite-q1-revenue-miss-in-line-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355778\" data-ts=\"1526039283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355778-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Dexcom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) initiated with Buy rating and $100 (18% upside) price target at BofA/Merrill Lynch.</li><li>Alkermes (NASDAQ:<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a>) initiated with Buy rating and $56 (22% upside) price target at BofA/Merrill Lynch.</li><li>National Health Investors (NYSE:<a href='https://seekingalpha.com/symbol/NHI' title='National Health Investors Inc.'>NHI</a>) upgraded to Overweight at CapitalOne.</li><li>Ultragenyx Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) upgraded to Overweight at Barclays.</li><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) upgraded to Overweight at Barclays. Shares up&nbsp;<font color='green'>2%</font>&nbsp;premarket.</li><li>Zymeworks (NYSE:<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks'>ZYME</a>) upgraded to Equal Weight with a $15 (flat) price target at Barclays.</li><li>Halozyme Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>) downgraded to Underweight at Barclays. Shares down&nbsp;<font color='red'>5%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3355778\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$DXCM $DXCM $ALKS - Premarket analyst action - healthcare https://seekingalpha.com/news/3355778-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3355778-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355777\" data-ts=\"1526039269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355777-nvidia-earnings-call-gpu-pricing-crypto-demand-and-tams\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia earnings call: GPU pricing, crypto demand, and TAMs</a></h4><ul><li>        Key takeaways from Nvidia&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) earnings call:</li><li>               GPU pricing was lighter earlier this quarter, but the company says the situation is now easing.&nbsp;</li><li>               Cryptocurrency demand was stronger-than-expected. Nvidia was able to fill most of the demand with crypto-specific GPUs, which fall under the OEM business. IN Q2, Nvidia expects crypto revenue to be about one-third of the level in Q1.&nbsp;</li><li>               Company sees a $50B TAM in Datacenter by 2023, up from the previous forecast of $30B by 2020.&nbsp;</li><li>               Nvidia sees self-driving vehicle TAM of $60B by 2035 and expects 100M autonomous passenger vehicles and 10M robot taxis by that date.&nbsp;</li><li>               Nvidia shares are&nbsp;<font color='red'>down 2.5%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355550-nvidia-minus-1_7-percent-q1-beats-upside-guide-strength-gaming-datacenter\" target=\"_blank\">Nvidia -1.7% after Q1 beats, upside guide, strength in Gaming and Datacenter</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355777\" data-linked=\"Nvidia earnings call: GPU pricing, crypto demand, and TAMs\" data-tweet=\"$NVDA - Nvidia earnings call: GPU pricing, crypto demand, and TAMs https://seekingalpha.com/news/3355777-nvidia-earnings-call-gpu-pricing-crypto-demand-and-tams?source=tweet\" data-url=\"https://seekingalpha.com/news/3355777-nvidia-earnings-call-gpu-pricing-crypto-demand-and-tams\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355771\" data-ts=\"1526038871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355771-rxi-pharmaceuticals-inks-deal-iovance-biotherapeutics-to-study-rnai-technology-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharmaceuticals inks deal with Iovance Biotherapeutics to study its RNAi technology for the advancement of immuno-oncology therapeutics</a></h4><ul><li>RXi Pharmaceuticals (RXII) has <a href=\"https://seekingalpha.com/pr/17160810-rxi-pharmaceuticals-enters-material-transfer-agreement-iovance-biotherapeutics-study-self\" target=\"_blank\">entered</a> into a research collaboration with Iovance Biotherapeutics to evaluate the potential synergies with RXi's sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer.</li> <li>Financial terms are not disclosed.</li><li>RXII shares up&nbsp;<font color='green'>11%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3355771\" data-linked=\"RXi Pharmaceuticals inks deal with Iovance Biotherapeutics to study its RNAi technology for the advancement of immuno-oncology therapeutics\" data-tweet=\"$PHIO - RXi Pharmaceuticals inks deal with Iovance Biotherapeutics to study its RNAi technology for the advancement of immuno-oncology therapeutics https://seekingalpha.com/news/3355771-rxi-pharmaceuticals-inks-deal-iovance-biotherapeutics-to-study-rnai-technology-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3355771-rxi-pharmaceuticals-inks-deal-iovance-biotherapeutics-to-study-rnai-technology-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3355773\" data-ts=\"1526038837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3355773-dropbox-reveals-upside-guidance-on-earnings-call-sharesminus-2_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dropbox reveals upside guidance on earnings call; shares -2.8%</a></h4><ul><li>        Dropbox (NASDAQ:<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox'>DBX</a>) reveals its guidance during the earnings call. Upside Q2 guidance has revenue from $328M to $331M (consensus: $324.92M).</li><li>               Upside FY18 guidance has revenue from $1.343 to $1.345B (consensus: $1.33B). &nbsp;&nbsp;</li><li>               Dropbox shares are&nbsp;<font color='red'>down 2.8%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3355500-dropboxs-first-earnings-report-beats-estimates\" target=\"_blank\">Dropbox's first earnings report beats estimates</a> (May 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3355773\" data-linked=\"Dropbox reveals upside guidance on earnings call; shares -2.8%\" data-tweet=\"$DBX - Dropbox reveals upside guidance on earnings call; shares -2.8% https://seekingalpha.com/news/3355773-dropbox-reveals-upside-guidance-on-earnings-call-sharesminus-2_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3355773-dropbox-reveals-upside-guidance-on-earnings-call-sharesminus-2_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}